Chemomab Therapeutics (CMMB) Accounts Payables (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Accounts Payables data on file, last reported at $485000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 23.38% year-over-year to $485000.0; the trailing twelve-month figure through Dec 2025 stood at $485000.0 (down 23.38% YoY), and the FY2025 full-year result was $485000.0, down 23.38% from the prior year.
• Accounts Payables for Q4 2025 stood at $485000.0, up from $194000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $2.3 million in Q2 2023 and bottomed at $194000.0 in Q3 2025.
• The 5-year median for Accounts Payables is $682000.0 (2023), against an average of $1.0 million.
• The widest annual swing landed in 2021, when Accounts Payables surged 1336.56%; it then sank 76.23% in 2024.
• A 5-year view of Accounts Payables shows it stood at $1.3 million in 2021, then increased by 26.35% to $1.7 million in 2022, then plunged by 69.43% to $516000.0 in 2023, then climbed by 22.67% to $633000.0 in 2024, then slipped by 23.38% to $485000.0 in 2025.
• The last three Accounts Payables figures came in at $485000.0 (Q4 2025), $194000.0 (Q3 2025), and $378000.0 (Q2 2025), per Business Quant data.

Peer Comparison